Molecular MRI quantification of extracellular aldehyde pairs for early detection of liver fibrogenesis and response to treatment
Yingying Ning, Iris Y. Zhou, Jesse D. Roberts, Nicholas J. Rotile, Eman A. Akam, Stephen C. Barrett, Mozhdeh Sojoodi, Matthew N. Barr, Tracy Punshon, Pamela Pantazopoulos, Hannah K. Drescher, Brian P. Jackson, Kenneth K. Tanabe, Peter Caravan
Abstract
Liver fibrosis plays a critical role in the evolution of most chronic liver diseases and is characterized by a buildup of extracellular matrix, which can progress to cirrhosis, hepatocellular carcinoma, liver failure, or death. Now, there are no noninvasive methods available to accurately assess disease activity (fibrogenesis) to sensitively detect early onset of fibrosis or to detect early response to treatment. Here, we hypothesized that extracellular allysine aldehyde (Lys Ald ) pairs formed by collagen oxidation during active fibrosis could be a target for assessing fibrogenesis with a molecular probe. We showed that molecular magnetic resonance imaging (MRI) using an extracellular probe targeting these Lys Ald pairs acts as a noninvasive biomarker of fibrogenesis and demonstrated its high sensitivity and specificity in detecting fibrogenesis in toxin- and dietary-induced mouse models, a cholestasis rat model of liver fibrogenesis, and in human fibrotic liver tissues. Quantitative molecular MRI was highly correlated with fibrogenesis markers and enabled noninvasive detection of early onset fibrosis and response to antifibrotic treatment, showing high potential for clinical translation.